In a phase 1 study published Oct. 27, 2026, in the Aesthetic Surgery Journal, giving trenibotulinumtoxinE, a fast-acting type E toxin, and then onabotulinumtoxinA 30 days later for frown lines raised no new safety concerns and no antibodies against either…
In a phase 3 trial published Oct. 24, 2026, in Aesthetic Surgery Journal, 60.0% of adults treated with trenibotulinumtoxinE met a strict frown-line goal at day 7 vs. 0.6% with placebo; the effect started at hour 8 and faded by…
In a randomized trial, a hyaluronic acid lip filler with lidocaine improved lip fullness in 91.1% of treated people at 8 weeks and was not inferior to an approved filler. About half of the responders kept the improvement through week…